Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This single-arm phase II interventional study aims to assess disease response to, and
toxicity of, a combination of obinutuzumab and atezolizumab, with or without radiotherapy, in
treatment naive Follicular Lymphoma.
The study will involve an induction phase and a maintenance phase for responding
participants, for up to 24 months. Response to treatment will be monitored using medical
imaging and clinical assessment.
Phase:
Phase 2
Details
Lead Sponsor:
Olivia Newton-John Cancer Research Institute
Collaborators:
Austin Health Ballarat Health Services Peter MacCallum Cancer Centre, Australia Roche Products Pty Limited Western Health